vs
Side-by-side financial comparison of JBT Marel Corp (JBTM) and Insulet Corporation (PODD). Click either name above to swap in a different company.
JBT Marel Corp is the larger business by last-quarter revenue ($1.0B vs $783.7M, roughly 1.3× Insulet Corporation). Insulet Corporation runs the higher net margin — 13.0% vs 5.3%, a 7.7% gap on every dollar of revenue. On growth, JBT Marel Corp posted the faster year-over-year revenue change (115.6% vs 31.2%). JBT Marel Corp produced more free cash flow last quarter ($83.5M vs $48.2M). Over the past eight quarters, JBT Marel Corp's revenue compounded faster (60.3% CAGR vs 33.2%).
JBT Marel Corporation, formerly known as JBT Corporation, or John Bean Technologies Corporation, is a food processing machinery and automated vehicle company. The company was incorporated in 2008 when FMC Technologies divested its non-energy businesses. The company is based in Chicago, Illinois and traces its history back to a company founded in 1884 by John Bean, an orchardist in Los Gatos, California.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
JBTM vs PODD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $783.7M |
| Net Profit | $53.1M | $101.6M |
| Gross Margin | 34.5% | 72.6% |
| Operating Margin | 7.2% | 18.7% |
| Net Margin | 5.3% | 13.0% |
| Revenue YoY | 115.6% | 31.2% |
| Net Profit YoY | 858.6% | 0.9% |
| EPS (diluted) | $1.04 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $783.7M | ||
| Q3 25 | $1.0B | $706.3M | ||
| Q2 25 | $934.8M | $649.1M | ||
| Q1 25 | $854.1M | $569.0M | ||
| Q4 24 | $467.6M | $597.5M | ||
| Q3 24 | $453.8M | $543.9M | ||
| Q2 24 | $402.3M | $488.5M | ||
| Q1 24 | $392.3M | $441.7M |
| Q4 25 | $53.1M | $101.6M | ||
| Q3 25 | $66.0M | $87.6M | ||
| Q2 25 | $3.4M | $22.5M | ||
| Q1 25 | $-173.0M | $35.4M | ||
| Q4 24 | $-7.0M | $100.7M | ||
| Q3 24 | $38.9M | $77.5M | ||
| Q2 24 | $30.7M | $188.6M | ||
| Q1 24 | $22.8M | $51.5M |
| Q4 25 | 34.5% | 72.6% | ||
| Q3 25 | 35.9% | 72.2% | ||
| Q2 25 | 35.8% | 69.7% | ||
| Q1 25 | 34.2% | 71.9% | ||
| Q4 24 | 38.4% | 72.1% | ||
| Q3 24 | 36.1% | 69.3% | ||
| Q2 24 | 35.6% | 67.7% | ||
| Q1 24 | 35.8% | 69.5% |
| Q4 25 | 7.2% | 18.7% | ||
| Q3 25 | 10.2% | 16.7% | ||
| Q2 25 | 5.2% | 18.7% | ||
| Q1 25 | -3.9% | 15.6% | ||
| Q4 24 | 3.4% | 18.3% | ||
| Q3 24 | 10.3% | 16.2% | ||
| Q2 24 | 6.7% | 11.2% | ||
| Q1 24 | 7.4% | 12.9% |
| Q4 25 | 5.3% | 13.0% | ||
| Q3 25 | 6.6% | 12.4% | ||
| Q2 25 | 0.4% | 3.5% | ||
| Q1 25 | -20.3% | 6.2% | ||
| Q4 24 | -1.5% | 16.9% | ||
| Q3 24 | 8.6% | 14.2% | ||
| Q2 24 | 7.6% | 38.6% | ||
| Q1 24 | 5.8% | 11.7% |
| Q4 25 | $1.04 | $1.42 | ||
| Q3 25 | $1.26 | $1.24 | ||
| Q2 25 | $0.07 | $0.32 | ||
| Q1 25 | $-3.35 | $0.50 | ||
| Q4 24 | $-0.22 | $1.38 | ||
| Q3 24 | $1.21 | $1.08 | ||
| Q2 24 | $0.95 | $2.59 | ||
| Q1 24 | $0.71 | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | — |
| Total DebtLower is stronger | $1.5B | $930.8M |
| Stockholders' EquityBook value | $4.5B | $1.5B |
| Total Assets | $8.2B | $3.2B |
| Debt / EquityLower = less leverage | 0.33× | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.5B | $930.8M | ||
| Q3 25 | $1.5B | $934.9M | ||
| Q2 25 | $1.5B | $939.0M | ||
| Q1 25 | $2.0B | $1.6B | ||
| Q4 24 | $1.3B | $1.3B | ||
| Q3 24 | $648.3M | $1.4B | ||
| Q2 24 | $647.7M | $1.4B | ||
| Q1 24 | $647.0M | $1.4B |
| Q4 25 | $4.5B | $1.5B | ||
| Q3 25 | $4.4B | $1.4B | ||
| Q2 25 | $4.4B | $1.5B | ||
| Q1 25 | $4.1B | $1.3B | ||
| Q4 24 | $1.5B | $1.2B | ||
| Q3 24 | $1.6B | $1.1B | ||
| Q2 24 | $1.5B | $998.4M | ||
| Q1 24 | $1.5B | $790.7M |
| Q4 25 | $8.2B | $3.2B | ||
| Q3 25 | $8.2B | $3.0B | ||
| Q2 25 | $8.3B | $3.5B | ||
| Q1 25 | $8.0B | $3.5B | ||
| Q4 24 | $3.4B | $3.1B | ||
| Q3 24 | $2.8B | $3.0B | ||
| Q2 24 | $2.7B | $2.9B | ||
| Q1 24 | $2.7B | $2.6B |
| Q4 25 | 0.33× | 0.61× | ||
| Q3 25 | 0.34× | 0.68× | ||
| Q2 25 | 0.35× | 0.64× | ||
| Q1 25 | 0.48× | 1.21× | ||
| Q4 24 | 0.81× | 1.07× | ||
| Q3 24 | 0.41× | 1.21× | ||
| Q2 24 | 0.43× | 1.36× | ||
| Q1 24 | 0.43× | 1.72× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $117.4M | $183.3M |
| Free Cash FlowOCF − Capex | $83.5M | $48.2M |
| FCF MarginFCF / Revenue | 8.3% | 6.2% |
| Capex IntensityCapex / Revenue | 3.4% | 17.2% |
| Cash ConversionOCF / Net Profit | 2.21× | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | $238.1M | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $117.4M | $183.3M | ||
| Q3 25 | $87.7M | $125.7M | ||
| Q2 25 | $102.2M | $196.5M | ||
| Q1 25 | $34.4M | $63.8M | ||
| Q4 24 | $128.7M | $147.7M | ||
| Q3 24 | $71.9M | $98.5M | ||
| Q2 24 | $21.6M | $96.5M | ||
| Q1 24 | $10.4M | $87.6M |
| Q4 25 | $83.5M | $48.2M | ||
| Q3 25 | $56.5M | $100.1M | ||
| Q2 25 | $83.7M | $177.9M | ||
| Q1 25 | $14.4M | $51.5M | ||
| Q4 24 | $118.7M | $94.1M | ||
| Q3 24 | $65.0M | $71.8M | ||
| Q2 24 | $11.1M | $74.0M | ||
| Q1 24 | $-100.0K | $65.5M |
| Q4 25 | 8.3% | 6.2% | ||
| Q3 25 | 5.6% | 14.2% | ||
| Q2 25 | 9.0% | 27.4% | ||
| Q1 25 | 1.7% | 9.1% | ||
| Q4 24 | 25.4% | 15.7% | ||
| Q3 24 | 14.3% | 13.2% | ||
| Q2 24 | 2.8% | 15.1% | ||
| Q1 24 | -0.0% | 14.8% |
| Q4 25 | 3.4% | 17.2% | ||
| Q3 25 | 3.1% | 3.6% | ||
| Q2 25 | 2.0% | 2.9% | ||
| Q1 25 | 2.3% | 2.2% | ||
| Q4 24 | 2.1% | 9.0% | ||
| Q3 24 | 1.5% | 4.9% | ||
| Q2 24 | 2.6% | 4.6% | ||
| Q1 24 | 2.7% | 5.0% |
| Q4 25 | 2.21× | 1.80× | ||
| Q3 25 | 1.33× | 1.43× | ||
| Q2 25 | 30.06× | 8.73× | ||
| Q1 25 | — | 1.80× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | 1.85× | 1.27× | ||
| Q2 24 | 0.70× | 0.51× | ||
| Q1 24 | 0.46× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JBTM
Segment breakdown not available.
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
